Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience
- 1 October 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (10) , 5374-5380
Abstract
Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretroviral therapy in infants and children to treat HIV infection. Dosing based on either weight or body surface area has been approved by the U.S. Food and Drug Administration (FDA) but can be difficult to implement in resource-limited settings. The World Health Organization (WHO) has developed simplified weight band dosing for NVP, but it has not been critically evaluated. NVP pharmacokinetic data were combined from eight pediatric clinical trials (Pediatric AIDS Clinical Trials Group [PACTG] studies 245, 356, 366, 377, 403, 1056, and 1069 and Children with HIV in Africa Pharmacokinetics and Adherence of Simple Antiretroviral Regimens [CHAPAS]) representing subjects from multiple continents and across the pediatric age continuum. A population pharmacokinetic model was developed to characterize developmental changes in NVP disposition, identify potential sources of NVP pharmacokinetic variability, and assess various pediatric dosing strategies and their impact on NVP exposure. Age, CYP2B6 genotype, and ritonavir were independent predictors of oral NVP clearance. The Triomune fixed-dose tablet was an independent predictor of bioavailability compared to the liquid and other tablet formulations. Monte Carlo simulations of the final model were used to assess WHO weight band dosing recommendations. The final pharmacokinetic model indicated that WHO weight band dosing is likely to result in a percentage of children with NVP exposure within the target range similar to that obtained with FDA dosing. Weight band dosing of NVP proposed by the WHO has the potential to provide a simple and effective dosing strategy for resource limited settings.Keywords
This publication has 27 references indexed in Scilit:
- Pharmacokinetics and Safety of a New Paediatric Fixed-Dose Combination of Zidovudine/Lamivudine/Nevirapine in HIV-Infected ChildrenAntiviral Therapy, 2011
- Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian PatientsAntimicrobial Agents and Chemotherapy, 2010
- A Chewable Pediatric Fixed-dose Combination Tablet of Stavudine, Lamivudine, and NevirapineThe Pediatric Infectious Disease Journal, 2010
- Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tabletsJournal of Antimicrobial Chemotherapy, 2009
- Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokineticsHIV Medicine, 2008
- Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety reviewHIV Medicine, 2007
- Efficacy, Tolerability and Pharmacokinetics of Two Nelfinavir-Based Regimens in Human Immunodeficiency Virus-Infected Children and AdolescentsThe Pediatric Infectious Disease Journal, 2005
- Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load ResponseaThe Journal of Infectious Diseases, 2005
- Population pharmacokinetics of nevirapine in an unselected cohort of HIV‐1‐infected individualsBritish Journal of Clinical Pharmacology, 2002
- Antiretroviral Pharmacokinetics in the Paediatric PopulationClinical Pharmacokinetics, 2002